A detailed history of Primecap Management CO transactions in Nektar Therapeutics stock. As of the latest transaction made, Primecap Management CO holds 5,912,453 shares of NKTR stock, worth $5.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,912,453
Previous 6,020,453 1.79%
Holding current value
$5.5 Million
Previous $7.47 Million 2.96%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$1.11 - $1.48 $119,880 - $159,840
-108,000 Reduced 1.79%
5,912,453 $7.69 Million
Q2 2024

Aug 09, 2024

SELL
$0.9 - $1.83 $851,574 - $1.73 Million
-946,194 Reduced 13.58%
6,020,453 $7.47 Million
Q1 2024

May 13, 2024

SELL
$0.49 - $0.96 $17,199 - $33,696
-35,100 Reduced 0.5%
6,966,647 $6.48 Million
Q4 2023

Feb 09, 2024

SELL
$0.42 - $0.57 $82,419 - $111,854
-196,236 Reduced 2.73%
7,001,747 $3.92 Million
Q3 2023

Nov 13, 2023

SELL
$0.51 - $1.05 $485,465 - $999,487
-951,893 Reduced 11.68%
7,197,983 $4.32 Million
Q2 2023

Aug 11, 2023

SELL
$0.53 - $1.03 $1.77 Million - $3.43 Million
-3,333,150 Reduced 29.03%
8,149,876 $4.73 Million
Q1 2023

May 15, 2023

SELL
$0.64 - $3.15 $2.67 Million - $13.2 Million
-4,176,027 Reduced 26.67%
11,483,026 $8.04 Million
Q4 2022

Feb 13, 2023

SELL
$2.03 - $4.28 $1.55 Million - $3.27 Million
-763,390 Reduced 4.65%
15,659,053 $35.4 Million
Q3 2022

Nov 14, 2022

SELL
$3.04 - $5.14 $391,792 - $662,438
-128,879 Reduced 0.78%
16,422,443 $52.6 Million
Q2 2022

Aug 11, 2022

SELL
$3.17 - $6.17 $1.62 Million - $3.15 Million
-510,500 Reduced 2.99%
16,551,322 $62.9 Million
Q1 2022

May 11, 2022

SELL
$4.16 - $13.72 $1.46 Million - $4.81 Million
-350,600 Reduced 2.01%
17,061,822 $92 Million
Q4 2021

Feb 11, 2022

SELL
$10.83 - $18.41 $6.14 Million - $10.4 Million
-567,100 Reduced 3.15%
17,412,422 $235 Million
Q3 2021

Nov 12, 2021

SELL
$13.07 - $18.84 $1.34 Million - $1.93 Million
-102,250 Reduced 0.57%
17,979,522 $323 Million
Q2 2021

Aug 10, 2021

SELL
$16.52 - $20.4 $1.38 Million - $1.71 Million
-83,597 Reduced 0.46%
18,081,772 $310 Million
Q1 2021

May 14, 2021

SELL
$16.56 - $25.46 $4.55 Million - $7 Million
-275,030 Reduced 1.49%
18,165,369 $363 Million
Q4 2020

Feb 08, 2021

SELL
$15.77 - $19.03 $6.72 Million - $8.11 Million
-426,230 Reduced 2.26%
18,440,399 $313 Million
Q3 2020

Nov 13, 2020

SELL
$16.59 - $24.79 $8.96 Million - $13.4 Million
-539,970 Reduced 2.78%
18,866,629 $313 Million
Q2 2020

Aug 13, 2020

SELL
$16.86 - $23.44 $18.1 Million - $25.2 Million
-1,076,320 Reduced 5.25%
19,406,599 $449 Million
Q1 2020

May 14, 2020

BUY
$14.47 - $27.96 $5.83 Million - $11.3 Million
402,571 Added 2.0%
20,482,919 $366 Million
Q4 2019

Feb 14, 2020

BUY
$15.87 - $23.12 $15.2 Million - $22.1 Million
957,126 Added 5.01%
20,080,348 $433 Million
Q3 2019

Nov 13, 2019

BUY
$16.91 - $36.27 $554,648 - $1.19 Million
32,800 Added 0.17%
19,123,222 $348 Million
Q2 2019

Aug 14, 2019

SELL
$31.0 - $36.3 $8.23 Million - $9.63 Million
-265,400 Reduced 1.37%
19,090,422 $679 Million
Q1 2019

May 14, 2019

SELL
$31.58 - $46.35 $1.4 Million - $2.05 Million
-44,200 Reduced 0.23%
19,355,822 $650 Million
Q4 2018

Feb 12, 2019

SELL
$30.43 - $56.65 $23 Million - $42.8 Million
-754,900 Reduced 3.75%
19,400,022 $638 Million
Q3 2018

Nov 13, 2018

SELL
$46.46 - $68.49 $34.8 Million - $51.2 Million
-748,000 Reduced 3.58%
20,154,922 $1.23 Billion
Q2 2018

Aug 13, 2018

SELL
$46.25 - $104.45 $7.35 Million - $16.6 Million
-158,973 Reduced 0.75%
20,902,922 $1.02 Billion
Q1 2018

May 14, 2018

SELL
$57.4 - $108.44 $74.4 Million - $140 Million
-1,295,627 Reduced 5.8%
21,061,895 $2.24 Billion
Q4 2017

Feb 13, 2018

SELL
$23.02 - $60.5 $18.1 Million - $47.5 Million
-784,700 Reduced 3.39%
22,357,522 $1.34 Billion
Q3 2017

Nov 13, 2017

BUY
$17.79 - $24.0 $412 Million - $555 Million
23,142,222
23,142,222 $555 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Primecap Management CO Portfolio

Follow Primecap Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.